261 related articles for article (PubMed ID: 30442634)
1. Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis.
Uchida S; Oiso N; Komeda Y; Kudo M; Kawada A
Eur J Dermatol; 2019 Aug; 29(4):444-445. PubMed ID: 30442634
[No Abstract] [Full Text] [Related]
2. Secukinumab-induced ulcerative colitis: opening Pandora's box of immunity.
Fernández-de la Varga M; Del Pozo-Del Valle P; Béjar-Serrano S; Garrido-Marín A; Bastida Paz G
Gastroenterol Hepatol; 2020; 43(7):358-359. PubMed ID: 32561217
[No Abstract] [Full Text] [Related]
3. A case of new onset ulcerative colitis following secukinumab treatment.
Johnston DN; Veettil R
Br J Hosp Med (Lond); 2019 Sep; 80(9):544-545. PubMed ID: 31498681
[No Abstract] [Full Text] [Related]
4. The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?
Rodríguez Moncada R; Vázquez Morón JM; Pallarés Manrique H
Rev Esp Enferm Dig; 2019 Sep; 111(9):720-721. PubMed ID: 31333036
[TBL] [Abstract][Full Text] [Related]
5. Severe colitis complicating secukinumab (Cosentyx
Lee ASW; Levell NJ; Shah SN; Gaffney K; Tremelling MAW
Clin Exp Dermatol; 2020 Apr; 45(3):344-345. PubMed ID: 31854471
[No Abstract] [Full Text] [Related]
6. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab.
Kolios AGA; Biedermann L; Weber A; Navarini AA; Meier J; Cozzio A; French LE
Br J Dermatol; 2018 Feb; 178(2):551-555. PubMed ID: 28477389
[TBL] [Abstract][Full Text] [Related]
7. First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab.
Sadik CD; Thieme M; Zillikens D; Terheyden P
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e406-e407. PubMed ID: 31131924
[No Abstract] [Full Text] [Related]
8. Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction.
Wollina U; Schönlebe J; Fürll C
Dermatol Ther; 2020 Jan; 33(1):e13161. PubMed ID: 31705566
[No Abstract] [Full Text] [Related]
9. Superficial thrombophlebitis during secukinumab treatment in a patient with psoriasis.
Mammadli K; Ceken K; Unal B; Karakas AA; Yilmaz E; Alpsoy E
Indian J Dermatol Venereol Leprol; 2020; 86(6):699-701. PubMed ID: 33037163
[No Abstract] [Full Text] [Related]
10. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Reich K; Leonardi C; Langley RG; Warren RB; Bachelez H; Romiti R; Ohtsuki M; Xu W; Acharya N; Solotkin K; Colombel JF; Hardin DS
J Am Acad Dermatol; 2017 Mar; 76(3):441-448.e2. PubMed ID: 28027825
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report.
Venturini M; Zanca A; Venturuzzo A; Filippini M; Frassi M; Tincani A; Calzavara-Pinton PG
J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e110-e112. PubMed ID: 31667904
[No Abstract] [Full Text] [Related]
12. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.
Hohenberger M; Cardwell LA; Oussedik E; Feldman SR
J Dermatolog Treat; 2018 Feb; 29(1):13-18. PubMed ID: 28521565
[TBL] [Abstract][Full Text] [Related]
13. New onset alopecia areata during secukinumab therapy.
Yalici Armagan B; Atakan N
Dermatol Ther; 2019 Sep; 32(5):e13071. PubMed ID: 31442356
[No Abstract] [Full Text] [Related]
14. Paradoxical exacerbation of latent interstitial pneumonia by secukinumab in a patient with psoriasis vulgaris.
Hayashi M; Igarashi A; Okamura K; Suzuki T
Br J Dermatol; 2019 Mar; 180(3):684-685. PubMed ID: 30430554
[No Abstract] [Full Text] [Related]
15. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy.
Hay RA; Pan JY
Clin Exp Dermatol; 2014 Aug; 39(6):751-2. PubMed ID: 24984757
[No Abstract] [Full Text] [Related]
16. IL-17 inhibitors for psoriasis.
Paek SY; Frieder J; Kivelevitch D; Menter MA
Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
[TBL] [Abstract][Full Text] [Related]
17. Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance.
Ferrières L; Konstantinou MP; Bulai Livideanu C; Hegazy S; Tauber M; Amelot F; Paul C
Clin Exp Dermatol; 2019 Oct; 44(7):e230-e234. PubMed ID: 31055846
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
Thaçi D; Puig L; Reich K; Tsai TF; Tyring S; Kingo K; Ziv M; Pinter A; Vender R; Lacombe A; Xia S; Bhosekar V; Gilloteau I; Guana A; Blauvelt A
J Am Acad Dermatol; 2019 Dec; 81(6):1405-1409. PubMed ID: 31399223
[No Abstract] [Full Text] [Related]
19. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
Ortiz-Salvador JM; Saneleuterio-Temporal M; Magdaleno-Tapial J; Velasco-Pastor M; Pujol-Marco C; Sahuquillo-Torralba A; Mateu-Puchades A; Pitarch-Bort G; Marí-Ruiz JI; Mataix-Díaz J; Montesinos-Villaescusa E; Miralles-Botella J; García-Fernández L; Martorell-Calatayud A; Belinchón-Romero I; Sánchez-Carazo JL; Pérez-Ferriols A
J Am Acad Dermatol; 2019 Aug; 81(2):427-432. PubMed ID: 30872150
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis Induced by Vedolizumab.
Sody E; Körber A
Inflamm Bowel Dis; 2017 Feb; 23(2):E9-E11. PubMed ID: 28107281
[No Abstract] [Full Text] [Related]
[Next] [New Search]
